If this is where you are
Newly diagnosedReports arriving, no plan yetAlready tested elsewhereYou have results you cannot readOn treatment nowYou want to know it is workingOr
Finished treatmentWatching for anything left behindWorried about familyInherited risk, and relativesWanting a second opinionA decision you are unsure aboutDecide
Blueprint CareThe flagship decision report and a dedicated clinical teamSignalOne free question answered on WhatsApp within four hoursNavigationRecords you already have, turned into a clarity timelineDecipherInterpretation of sequencing already done elsewhereTest
Signature, all tiersSolid tumour and blood cancer panels comparedSignature STb33 genes from a blood drawSignature STb O118 genes from a blood drawSignature STb O+523 genes, with TMB and MSISignature STt OProfiling from an existing tissue blockMonitor
SentinelSerial monitoring while treatment is runningSentinel SolidctDNA monitoring for solid tumoursClearMolecular residual disease surveillanceClear SolidTumour-informed surveillanceProtect
HeritageInherited risk, assessed properlyHeritage CoreA broad inherited-risk assessmentHeritage AdhocFocused testing for named relativesCancer DictionaryWhat is discussed in your specific cancerReference
Cancer DictionaryOne structured entry per cancer typeBiomarker LibraryOne page per marker, in plain languagePatient ResourcesGlossary, guides and how to use themWatch, read and ask
Video LibraryShort explainers, captioned and translatedStoriesPatient and clinician experiences, consentedFAQThe questions we are asked mostCancer Dictionary · Gynaecological
Nearly all cervical cancer arises from persistent infection with high-risk human papillomavirus. Because the cause is known and both a vaccine and effective screening exist, the disease is unusual in oncology: the most consequential interventions happen before cancer develops. In advanced or recurrent disease, immune markers and a limited set of genomic findings enter the discussion.
Also called Carcinoma of the cervix.
Start here
Cervical cancer is driven overwhelmingly by persistent HPV infection, which makes prevention and screening the dominant story and places genomic profiling in a narrower supporting role, mainly in advanced disease.
Nearly all cervical cancer arises from persistent infection with high-risk human papillomavirus. Because the cause is known and both a vaccine and effective screening exist, the disease is unusual in oncology: the most consequential interventions happen before cancer develops. In advanced or recurrent disease, immune markers and a limited set of genomic findings enter the discussion.
01Before any molecular question
Usually established first: histological subtype (squamous cell carcinoma, adenocarcinoma or other), stage, and HPV status. Staging in cervical cancer has a clinical component that distinguishes it from many other solid tumours.
Usually already established
02
The divisions below are not labels. Each one changes what the treatment discussion is actually about.
Pre-invasive disease
Detected by screening. Managed to prevent progression rather than to treat cancer. This is where the greatest impact is available.
Early stage, localised
Surgery or radiation-based approaches organise the discussion. Fertility preservation is frequently part of it.
Locally advanced
Chemoradiation dominates. Molecular profiling rarely changes this decision.
Recurrent or metastatic
The setting where PD-L1 status and profiling are most often discussed, and where trial options become relevant.
03What is discussed
PD-L1 expression is the marker most consistently discussed in recurrent or metastatic disease. PIK3CA is the most frequently altered gene. ERBB2 alterations, KRAS, STK11, PTEN and high tumour mutational burden also appear. HPV integration status and viral genotype are of research interest. Tissue factor expression is relevant to specific antibody-drug conjugate approaches. Genomic profiling in cervical cancer is generally a later-line consideration rather than a first-line one.
HPV
The cause rather than a treatment target. Genotype and persistence matter for prevention and screening.
PD-L1
The marker most often discussed in recurrent or metastatic disease.
PIK3CA
The most frequently altered gene in this disease.
TMB
Assessed in advanced disease as part of the immunotherapy discussion.
MMR / MSI
Uncommon, but assessed in advanced disease.
ERBB2 (HER2)
Occasionally found, and relevant to specific treatment classes.
This is not an exhaustive list, and which markers are relevant depends on the individual case. Not every marker listed is assessed in every patient.
04What is tested, and from what
Comprehensive profiling is not usually part of early-stage management, where the treatment path is well defined by stage. In recurrent or metastatic disease it is more often discussed, typically alongside PD-L1 assessment, and frequently in the context of trial access. Tissue is generally available from the diagnostic biopsy or surgical specimen.
Cervical cancer is not typically an inherited-risk disease. Germline testing is not part of the routine discussion unless there are other features in the personal or family history pointing elsewhere.
Cancer genetics and hereditary riskCirculating HPV DNA is under active study as a marker of residual and recurrent disease, and is a distinctive feature of this cancer: the marker being tracked is viral rather than human. Tumour ctDNA is studied alongside it.
More on ctDNA monitoring05The timing question
Testing that arrives after the decision it was meant to inform has already been made is a common and avoidable problem. This is the sequence in which molecular information tends to become relevant.
06Take these to your team
When a decision is being made
Questions worth raising with a treating team.
At progression, recurrence or resistance
The molecular picture at diagnosis is not always the molecular picture later.
07What shapes eligibility
Trial activity in recurrent and metastatic cervical cancer is substantial, centred on immune approaches, antibody-drug conjugates and HPV-directed strategies. PD-L1 status and prior therapy commonly determine eligibility.
| Term | What it means |
|---|---|
| HPV | Human papillomavirus. Persistent infection with high-risk types is the cause of nearly all cervical cancer. |
| Pre-invasive disease | Abnormal cells that have not yet invaded. Treatable in a way that prevents cancer entirely. |
| Chemoradiation | Chemotherapy given alongside radiation to increase its effect. |
| Circulating HPV DNA | Viral DNA measurable in blood, under study as a marker of residual disease. |
These are the services most often relevant to this cancer. Which of them applies is a clinical question, not an automatic one.
This entry is educational. It describes what is commonly discussed in this cancer, not what should happen for any individual. Which of it applies depends on the specific diagnosis, stage, prior treatment and the person themselves. Nothing here is a recommendation, and no list of biomarkers here is exhaustive. Decisions belong with a treating team who know the whole case.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal